Search Results - Suzanne Trudel

Refine Results
  1. 1
    Antibodies and bispecifics for multiple myeloma: effective effector therapy

    Antibodies and bispecifics for multiple myeloma: effective effector therapy by Christopher Cipkar, Christine Chen, Suzanne Trudel

    Published 2022
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Actin assembly in electropermeabilized neutrophils: role of intracellular calcium.

    Actin assembly in electropermeabilized neutrophils: role of intracellular calcium. by Gregory P. Downey, C K Chan, Suzanne Trudel, Sergio Grinstein

    Published 1990
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma

    Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma by Hong Chang, A. Keith Stewart, Qi Xiao, Zhihua Li, Qi Long Yi, Suzanne Trudel

    Published 2005
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma

    Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma by Suzanne Trudel, Zhihua Li, Jennifer Rauw, Rodger E. Tiedemann, Xiao‐Yan Wen, A. Keith Stewart

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma

    Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma by Suzanne Trudel, Scott Ely, Yildiz Farooqi, Maurizio Affer, Davide F. Robbiani, Marta Chesi, P. Leif Bergsagel

    Published 2004
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Clinical Outcomes in t(4;14) Multiple Myeloma: A Chemotherapy-Sensitive Disease Characterized by Rapid Relapse and Alkylating Agent Resistance

    Clinical Outcomes in t(4;14) Multiple Myeloma: A Chemotherapy-Sensitive Disease Characterized by Rapid Relapse and Alkylating Agent Resistance by Wilfrid Jaksic, Suzanne Trudel, Hong Chang, Young Trieu, Qi Xi, Joseph Mıkhael, Donna Reece, Christine Chen, A. Keith Stewart

    Published 2005
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma

    CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma by Suzanne Trudel, Zhihua Li, Ellen Wei, Marion Wiesmann, Hong Chang, Christine Chen, Donna Reece, Carla Heise, A. Keith Stewart

    Published 2004
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma

    Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma by Donna Reece, Giovanni Piza Rodriguez, Christine Chen, Suzanne Trudel, Vishal Kukreti, Joseph Mıkhael, Mariela Pantoja, Wei Xu, A. Keith Stewart

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival

    Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival by Víctor H. Jiménez‐Zepeda, Joseph Mıkhael, Andrew Winter, Norman Franke, Esther Masih‐Khan, Suzanne Trudel, Christine Chen, Vishal Kukreti, Donna Reece

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma

    Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma by James W. Clendening, Aleksandra A. Pandyra, Zhihua Li, Paul C. Boutros, Աննա Մարտիրոսյան, Richard Lehner, Igor Jurišica, Suzanne Trudel, Linda Z. Penn

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development

    The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development by Pralay Mukhopadhyay, Hesham Abdullah, Joanna Opalinska, Prani Paka, Eric Richards, Katja Weisel, Suzanne Trudel, María‐Victoria Mateos, Meletios Α. Dimopoulos, Sagar Lonial

    Published 2025
    Get full text
    Revisão
    Save to List
    Saved in:
  12. 12
    D(T)<scp>PACE</scp> as salvage therapy for aggressive or refractory multiple myeloma

    D(T)<scp>PACE</scp> as salvage therapy for aggressive or refractory multiple myeloma by Alina S. Gerrie, Joseph Mıkhael, Lu Cheng, Haiyan Jiang, Vishal Kukreti, Tony Panzarella, Donna Reece, Keith Stewart, Young Trieu, Suzanne Trudel, Christine I. Chen

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    MIP-1α (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma

    MIP-1α (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma by Esther Masih‐Khan, Suzanne Trudel, Carla Heise, Zhihua Li, Joshua Paterson, Vincent Nadeem, Ellen Wei, David Roodman, Jaime O. Claudio, P. Leif Bergsagel, A. Keith Stewart

    Published 2006
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Immediate Utility of Two Approved Agents to Target Both the Metabolic Mevalonate Pathway and Its Restorative Feedback Loop

    Immediate Utility of Two Approved Agents to Target Both the Metabolic Mevalonate Pathway and Its Restorative Feedback Loop by Aleksandra A. Pandyra, Peter Mullen, Manpreet Kalkat, Rosemary Yu, Janice T. Pong, Zhihua Li, Suzanne Trudel, Karl S. Lang, Mark D. Minden, Aaron D. Schimmer, Linda Z. Penn

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma

    A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma by Melissa Alsina, Suzanne Trudel, Richard R. Furman, Peter J. Rosen, Owen A. O’Connor, Raymond L. Comenzo, Alvin Wong, Lori Kunkel, Christopher J. Molineaux, André Goy

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Antagonism of the Stat3–Stat3 Protein Dimer with Salicylic Acid Based Small Molecules

    Antagonism of the Stat3–Stat3 Protein Dimer with Salicylic Acid Based Small Molecules by Steven Fletcher, Brent D. G. Page, Xiaolei Zhang, Peibin Yue, Zhihua Li, Sumaiya Sharmeen, Jagdeep Singh, Wei Zhao, Aaron D. Schimmer, Suzanne Trudel, James Turkson, Patrick T. Gunning

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain

    Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain by Brent D. G. Page, Steven Fletcher, Peibin Yue, Zhihua Li, Xiaolei Zhang, Sumaiya Sharmeen, Alessandro Datti, Jeffrey L. Wrana, Suzanne Trudel, Aaron D. Schimmer, James Turkson, Patrick T. Gunning

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial

    Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial by Suzanne Trudel, Arleigh McCurdy, Martha L Louzada, Stephen Parkin, Darrell White, Michael P. Chu, Rami Kotb, Hira Mian, Ibraheem Othman, Jiandong Su, Aniba Khan, Engin Gul, Donna Reece

    Published 2024
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

    Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study by Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat, Peter M. Voorhees, Brandi Reeves, Edward N. Libby, Paul G. Richardson, Axel Hoos, Ira Gupta, Véronique Bragulat, Zangdong He, Joanna Opalinska, Adam D. Cohen

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity

    Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Synd... by Suzanne Trudel, Nizar J. Bahlis, Andrew Spencer, Rayan Kaedbey, Paula Rodríguez‐Otero, Simon J. Harrison, Chihunt Wong, Grant R. Goodman, Rin Nakamura, Voleak Choeurng, James Fenimore Cooper, María‐Victoria Mateos

    Published 2022
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: